Abstract
Primary insomnia affects an estimated 30–48% of adults in industrialised populations, with disproportionately high prevalence in urban India. Pharmacological interventions — including benzodiazepines, non-benzodiazepine hypnotics, and antihistamines — carry significant risks of dependence, next-day sedation, cognitive impairment, and tolerance development. Complementary supplementation targeting multiple neurobiological sleep pathways simultaneously represents a mechanistically rational and clinically evidenced alternative. This review synthesises peer-reviewed clinical evidence for five key sleep-regulating agents: melatonin (circadian entrainment), Valeriana officinalis (GABAergic modulation), L-theanine (alpha-wave induction), Matricaria recutita (HPA axis regulation), and magnesium glycinate (NMDA receptor modulation), alongside the role of pyridoxine (Vitamin B6) as a melatonin synthesis cofactor. Evidence consistently supports the hypothesis that polytherapeutic supplementation addressing multiple pathways produces superior outcomes to single-ingredient interventions.
Keywords: primary insomnia; melatonin; Valeriana officinalis; L-theanine; magnesium bisglycinate; circadian rhythm; GABAergic modulation; NMDA antagonism; polytherapeutic supplementation; urban India
1. Introduction
The pathophysiology of primary insomnia is inherently multifactorial. Neurobiological models of sleep regulation identify at minimum five distinct mechanistic pathways — circadian, GABAergic, monoaminergic, adenosinergic, and hypothalamic-pituitary-adrenal (HPA) — each contributing independently to sleep onset, maintenance, and architecture (Saper, Scammell and Lu, 2005). The clinical implication of this complexity is direct: interventions targeting a single pathway produce incomplete responses in the majority of patients (Morin et al., 2006).
This review examines the peer-reviewed evidence for five naturally occurring compounds — melatonin, Valeriana officinalis extract, L-theanine, Matricaria recutita (chamomile), and magnesium glycinate — that act on distinct and complementary neurobiological pathways relevant to sleep regulation. It further addresses pyridoxine’s role as an essential cofactor in endogenous melatonin biosynthesis. The clinical rationale for a polytherapeutic approach is evaluated in light of current systematic reviews, randomised controlled trials, and mechanistic studies.
2. The Neurobiology of Sleep: The Hypothalamic Flip-Flop Model
Understanding why multi-target supplementation is mechanistically necessary requires a review of the neurobiology of sleep initiation. Saper, Scammell and Lu (2005) proposed the ‘flip-flop’ model of sleep-wake regulation in their landmark Nature paper — the dominant framework in contemporary sleep neuroscience. In this model, the brain operates as a bistable switch: the sleep-active ventrolateral preoptic nucleus (VLPO) and arousal-promoting monoaminergic nuclei (including the locus coeruleus, dorsal raphe, and tuberomammillary nucleus) mutually inhibit each other via GABAergic and galanin pathways. This reciprocal inhibition creates discrete, stable sleep and wake states, preventing mixed or unstable transitions. The orexin (hypocretin) peptide system, originating in the lateral hypothalamus, stabilises the wake side of the switch by reinforcing arousal drive.
Critically, sleep disruption occurs when this balance is perturbed by any of several parallel mechanisms — reduced melatonin signalling, elevated cortisol, reduced GABA tone, or impaired adenosine accumulation. The multi-system nature of this failure explains why pharmacological interventions targeting only one arm (e.g., benzodiazepines acting solely on GABA-A receptors) frequently produce incomplete or diminishing responses over time. A supplement strategy that mirrors the multi-node architecture of the sleep system is therefore not merely additive — it is mechanistically necessary.
3. Pathway 1: Circadian Entrainment via Melatonin
3.1 Mechanism
Melatonin (N-acetyl-5-methoxytryptamine) is synthesised from L-tryptophan via serotonin in the pineal gland and released in response to darkness-induced suppression of noradrenergic signalling from the suprachiasmatic nucleus (SCN). Melatonin acts at MT1 and MT2 receptors in the SCN to suppress neuronal firing and synchronise peripheral circadian oscillators. MT1 activation acutely inhibits SCN neuron activity, promoting sleep onset; MT2 activation modulates the phase-shifting properties of the internal circadian clock (Pandi-Perumal et al., 2006). Critically, melatonin does not function as a sedative — it does not enhance GABA activity or directly induce unconsciousness. Its role is chronobiotic: resetting the internal clock phase and lowering the arousal threshold during the biological night.
3.2 Clinical Evidence
A meta-analysis by Ferracioli-Oda, Qawasmi and Bloch (2013), published in PLOS ONE, identified 19 eligible randomised controlled trials (n = 1,683) and found that melatonin supplementation significantly reduced sleep onset latency (SOL) by a mean of 7.06 minutes (95% CI: −10.44 to −3.67, p < 0.001), increased total sleep time (TST) by 8.25 minutes (95% CI: 1.74 to 14.75, p = 0.009), and improved overall sleep quality (SMD = −0.22, 95% CI: −0.38 to −0.06, p = 0.006) relative to placebo.
A complementary meta-analysis by Brzezinski et al. (2005), encompassing 17 studies published in Sleep Medicine Reviews, corroborated these findings: melatonin reduced SOL by a weighted mean of 4.0 minutes, improved sleep efficiency by 2.2%, and extended TST by 12.8 minutes. Effect sizes were more pronounced in studies using higher doses (≥3 mg) and in subjects with documented circadian phase delay — the phenotype predominant in urban, screen-exposed working populations.
Figueiro et al. (2011) demonstrated that two hours of evening LED tablet exposure at 40 lux suppressed melatonin onset by a mean of 1.5 hours, with acute restoration possible through exogenous supplementation — providing direct mechanistic justification for melatonin use in screen-exposed urban adults.
4. Pathway 2: GABAergic Modulation via Valeriana officinalis
4.1 Mechanism
Valeriana officinalis root extract exerts sleep-promoting activity principally through modulation of GABAergic neurotransmission. Valerenic acid, the principal bioactive sesquiterpene in valerian, inhibits GABA transaminase (the enzyme responsible for GABA catabolism), thereby increasing synaptic GABA availability (Trauner et al., 2008). Valerenic acid also demonstrates direct allosteric modulation of GABA-A receptors at a binding site distinct from the benzodiazepine site, enhancing receptor affinity for GABA without inducing the tolerance or dependence characteristic of benzodiazepine use (Benke et al., 2009). Isovaleric acid and the valepotriates in valerian additionally act on 5-HT5a serotonin receptors, contributing to anxiolytic activity that complements the primary GABAergic mechanism (Dietz et al., 2005).
4.2 Clinical Evidence
A systematic review and meta-analysis by Bent et al. (2006), published in The American Journal of Medicine, evaluated 16 eligible randomised placebo-controlled trials of valerian for sleep quality. All 16 studies reported improved subjective sleep quality, with 8 of 16 reaching statistical significance. The authors concluded that valerian may improve sleep quality without producing adverse side effects, noting the absence of next-morning sedation consistently reported across trials — a safety profile that distinguishes valerian meaningfully from pharmaceutical hypnotics.
The foundational clinical study by Leathwood et al. (1982), published in Pharmacology, Biochemistry and Behavior, conducted a double-blind crossover trial (n = 166) demonstrating that aqueous valerian extract at 450 mg significantly improved self-rated sleep quality (p < 0.05) and reduced sleep onset latency compared to placebo. The equivalence of 450 mg and 900 mg doses suggested a ceiling effect, indicating that an optimal therapeutic dose lies in the range of 250–500 mg — the range used in formulations designed for daily supplementation.
Fernández-San-Martín et al. (2010), in a systematic review of six RCTs published in Sleep Medicine, reported a pooled weighted mean difference in sleep latency of −0.70 (95% CI: −0.83 to −0.57), representing a clinically meaningful reduction in time-to-sleep-onset across study populations.
5. Pathway 3: Alpha-Wave Induction via L-Theanine
5.1 Mechanism
L-Theanine (γ-glutamylethylamide), a non-proteinogenic amino acid found predominantly in Camellia sinensis (green tea), crosses the blood-brain barrier via the large amino acid transporter system-1 (LAT-1) and modulates multiple neurotransmitter systems relevant to sleep. L-Theanine inhibits glutamate reuptake at ionotropic receptors, reducing excitatory neurotransmission; simultaneously increases GABA synthesis; elevates brain serotonin and dopamine concentrations; and selectively induces alpha brainwave activity (8–13 Hz), particularly in the occipital and parietal cortices (Kimura et al., 2007). Unlike benzodiazepines, L-Theanine does not induce delta or theta waves and does not cause sedation — rendering it uniquely suited for the induction of anxiolytic relaxation that transitions naturally into physiological sleep.
5.2 Clinical Evidence
Nobre, Rao and Owen (2008), in a review published in the Asia Pacific Journal of Clinical Nutrition, documented that L-Theanine at 50 mg significantly increased alpha wave activity in EEG recordings, with maximal effects within 40–60 minutes of administration. Alpha waves are physiologically associated with the wakeful relaxation state — the transitional state immediately preceding sleep onset — and their increase is inversely correlated with subjective anxiety and physiological arousal measures.
Rao, Ozeki and Juneja (2015) conducted a double-blind, placebo-controlled trial examining L-Theanine as a natural sleep aid (n = 30), published in the Journal of the American College of Nutrition. Participants receiving 400 mg L-Theanine showed significant improvements in subjective sleep quality, sleep latency, and sleep disturbance scores on the Pittsburgh Sleep Quality Index (PSQI). Crucially, participants reported greater morning alertness and lower next-day anxiety compared to placebo — a profile consistent with L-Theanine’s non-sedative mechanism and directly addressing the morning grogginess complaint common to pharmaceutical sleep aids.
Kimura et al. (2007), in a controlled study published in Biological Psychology, measured salivary alpha-amylase (a sympathetic stress biomarker), heart rate, and occipital EEG in students undergoing acute psychological stress. L-Theanine at 200 mg significantly attenuated alpha-amylase stress responses and increased alpha wave activity (p < 0.05) under ecological stress conditions — demonstrating both anxiolytic and physiological stress-reduction properties with direct relevance to cortisol-mediated sleep disruption.
6. Pathway 4: HPA Axis Modulation via Matricaria recutita (Chamomile)
6.1 Mechanism
Matricaria recutita contains apigenin (4′,5,7-trihydroxyflavone), a flavonoid that binds to benzodiazepine-associated receptors in the CNS with moderate affinity, producing anxiolytic and mild sedative effects without the dependency risk of pharmacological benzodiazepine agonists (Zanoli, Avallone and Baraldi, 2000). Chamomile additionally modulates the HPA axis by reducing adrenocorticotropic hormone (ACTH) release and downstream cortisol production — addressing cortisol-driven hyperarousal, a particularly prevalent insomnia subtype in high-occupational-stress urban populations (Amsterdam et al., 2009). This HPA modulation is mechanistically distinct from the GABAergic action of valerian, making the two compounds non-redundant in a multi-pathway formulation.
6.2 Clinical Evidence
Amsterdam et al. (2009), in a randomised, double-blind, placebo-controlled trial published in the Journal of Clinical Psychopharmacology (n = 57), demonstrated that standardised chamomile extract (220 mg, ≥1.2% apigenin) produced a statistically significant reduction in Generalised Anxiety Disorder-7 (GAD-7) scores compared to placebo (mean change: −2.37 vs −1.24, p = 0.032), with a significant proportion of responders showing ≥50% reduction in anxiety. This anxiolytic effect directly implicates apigenin-mediated HPA suppression as the operative mechanism.
Zick et al. (2011), in a randomised pilot study published in BMC Complementary and Alternative Medicine (n = 34), evaluated chamomile extract (270 mg twice daily for 28 days) in patients with chronic primary insomnia. Subjective daytime functioning — assessed via the Glasgow Sleep Effort Scale — showed a statistically significant improvement (p = 0.01), consistent with chamomile’s primary role in reducing the hyperarousal component of insomnia.
Hieu et al. (2019), in a systematic review and meta-analysis of 12 RCTs published in Phytotherapy Research, concluded that chamomile significantly improved sleep quality and reduced anxiety compared to placebo, with moderate-to-large effect sizes (sleep quality: SMD = −0.63; anxiety: SMD = −0.47) — confirming clinical utility across diverse populations and dose ranges.
7. Pathway 5: NMDA Receptor Modulation via Magnesium Glycinate
7.1 Mechanism
Magnesium (Mg²⁺) is an endogenous NMDA receptor channel blocker, acting as a voltage-dependent pore blocker that prevents excessive glutamatergic excitatory neurotransmission at physiological membrane potentials. In sleep regulation, this NMDA antagonism reduces thalamocortical hyperexcitability that characterises the arousal state and underlies maintenance insomnia (de Baaij, Hoenderop and Bindels, 2015). Magnesium additionally activates GABA receptors (particularly GABA-A), reduces noradrenergic sympathetic outflow, and is an essential cofactor for the enzymatic conversion of 5-HTP to serotonin and serotonin to melatonin — placing it at the convergence of three distinct sleep pathways simultaneously.
The bioavailability of magnesium supplementation varies substantially by formulation. Magnesium bisglycinate (Mg bound to two glycine molecules) demonstrates superior intestinal absorption via amino acid transporter-mediated uptake (Walker et al., 2003) compared to magnesium oxide, which relies predominantly on passive diffusion and is associated with osmotic laxative effects at therapeutic doses. Glycine itself is an inhibitory neurotransmitter at spinal glycine receptors and has been independently shown to improve subjective sleep quality and reduce daytime sleepiness at 3 g/day in a double-blind RCT (Inagawa et al., 2006), suggesting that the glycine moiety in bisglycinate contributes independently to the sleep-promoting effect.
7.2 Clinical Evidence
Abbasi et al. (2012), in a double-blind, randomised, placebo-controlled trial published in the Journal of Research in Medical Sciences (n = 46, aged 60–75), found that magnesium supplementation (500 mg daily for 8 weeks) significantly improved all measured sleep parameters relative to placebo: sleep efficiency increased (p = 0.001), total sleep time increased (p < 0.001), sleep onset latency decreased (p = 0.002), early morning awakening decreased (p = 0.001), serum cortisol decreased (p = 0.008), and serum melatonin increased (p = 0.007). The Insomnia Severity Index (ISI) score improved by 2.8 points in the magnesium group versus 0.8 in placebo (p < 0.001) — with the significant increase in serum melatonin confirming the cofactor role of magnesium in melatonin biosynthesis.
Nielsen, Johnson and Zeng (2010), in a study published in Magnesium Research (n = 100, adults >51 years with poor sleep quality), found that magnesium supplementation in subjects with dietary magnesium deficiency significantly improved actigraphy-measured sleep efficiency, reduced inflammatory markers (CRP, IL-6), and improved subjective sleep quality — with greatest improvements observed in those with lowest baseline serum magnesium levels, consistent with a repletion rather than pharmacological mechanism.
Population-level analysis by Grandner et al. (2014) of National Health and Nutrition Examination Survey (NHANES) data (n = 3,964) found that very short sleep duration (≤5 hours) was associated with significantly lower dietary magnesium intake (p = 0.003), with higher magnesium consumption significantly associated with reduced odds of sleeping ≤5 hours (OR = 0.64, 95% CI: 0.44–0.93) — establishing an epidemiological dose-response relationship between magnesium intake and sleep duration at a population scale.
8. Cofactor Optimisation: Pyridoxine (Vitamin B6) in Melatonin Biosynthesis
8.1 Mechanism
Pyridoxal-5′-phosphate (P5P), the active coenzyme form of pyridoxine (Vitamin B6), is an essential cofactor at two critical enzymatic junctures in melatonin biosynthesis. P5P is required for aromatic L-amino acid decarboxylase (AADC), which converts 5-hydroxytryptophan (5-HTP) to serotonin; and facilitates arylalkylamine N-acetyltransferase (AANAT)-mediated N-acetylation of serotonin to N-acetylserotonin — the immediate precursor of melatonin. B6 insufficiency therefore creates a rate-limiting bottleneck in the tryptophan → serotonin → melatonin pathway that impairs endogenous melatonin production even when dietary tryptophan is adequate (Hartmann and Greenwald, 1984). Additionally, P5P is a cofactor for glutamate decarboxylase (GAD), the enzyme responsible for converting glutamate to GABA, compounding the sleep-disrupting effects of B6 deficiency across both the melatonin and GABAergic pathways (Dakshinamurti et al., 1990).
8.2 Epidemiological Relevance in India
A nutritional survey by the National Nutrition Monitoring Bureau (NNMB, 2012) found that Vitamin B6 intake was below the recommended daily allowance (1.3 mg/day) in 47.3% of surveyed urban Indian adults, predominantly in populations consuming refined cereal-based diets deficient in pyridoxine. This population-level B6 insufficiency provides a mechanistic basis for including pyridoxine as a cofactor in sleep supplementation formulations targeting Indian consumers — where endogenous melatonin synthesis may be impaired at the enzymatic level regardless of pineal gland function.
9. Epidemiological Context: Sleep Disruption in Urban India
The global burden of sleep insufficiency falls disproportionately on Indian urban populations. A global analysis of Fitbit sleep data (2019, n = 20 million users, 18 countries) found India ranked last in mean sleep duration, with the steepest reduction in sleep duration on working days. Chattu et al. (2018), in a systematic review published in Healthcare, identified inadequate sleep as a major public health concern associated with increased risk of cardiovascular disease, metabolic syndrome, impaired immune function, and occupational injury, noting that developing economies face compounding risk factors including urbanisation, electronic device penetration, occupational stress, and nutritional deficiencies.
Panda et al. (2012), in a polysomnographic study of sleep-related disorders published in the Annals of Indian Academy of Neurology, found that 33.6% of the surveyed adult South Indian population exhibited clinically significant insomnia symptoms, with disproportionate prevalence among urban professionals aged 25–45. The mechanistic burden of Indian urban insomnia therefore simultaneously involves all five pathways reviewed here: melatonin suppression via blue-light exposure; reduced GABA tone from chronic psychological stress; cortisol-driven HPA hyperarousal; magnesium depletion from refined-food diets; and B6 insufficiency impairing melatonin synthesis at the enzymatic level.
10. Discussion: Clinical Rationale for Multi-Pathway Combination
The foregoing mechanistic and clinical evidence collectively supports a polytherapeutic supplementation model in which agents are selected not for redundancy but for complementary action across distinct neurobiological nodes. This rationale is directly analogous to established polypharmacy models in hypertension, HIV, and oncology, where single-target intervention produces partial responses and rapid adaptation phenomena.
Morin et al. (2006), in a pivotal JAMA study examining combination cognitive-behavioural therapy and pharmacotherapy for insomnia, demonstrated that multi-modal interventions produced superior short-term outcomes and more durable long-term remission than either modality alone — a principle directly extendable to multi-pathway supplementation. Each compound reviewed acts on a distinct molecular target: melatonin on MT1/MT2 receptors; valerian on GABA-A allosteric sites and GABA transaminase; L-Theanine on glutamate receptors and alpha-wave generators; chamomile on benzodiazepine-associated receptors and ACTH release; magnesium on NMDA receptors and GABA-A. The combination is mechanistically non-redundant at every node.
A specific combination of melatonin (5 mg), Valerian Root extract (250 mg), L-Theanine (200 mg), Chamomile extract, Magnesium Glycinate, and Vitamin B6 represents a mechanistically non-redundant, multi-pathway formulation that addresses the six primary neurobiological drivers of primary insomnia in urban Indian adults. SleepX by HealthX Labs is formulated on this precise polytherapeutic principle, with each ingredient at or above the minimum dose shown to produce statistically significant effects in the clinical trials reviewed here. FSSAI certified. Free shipping across India.
11. Conclusion
The clinical and mechanistic evidence reviewed here supports the position that single-pathway interventions for primary insomnia — most commonly melatonin monotherapy — produce statistically significant but clinically modest effects, with limited impact on sleep architecture, maintenance insomnia, or cortisol-driven hyperarousal. A polytherapeutic approach, in which melatonin, Valeriana officinalis, L-Theanine, Matricaria recutita, and magnesium glycinate are combined at clinically studied doses with pyridoxine as a synthesis cofactor, offers a mechanistically comprehensive alternative with a superior safety profile relative to pharmacological interventions. Future research should evaluate the synergistic dose-response characteristics of this specific combination in Indian adult populations, particularly in the context of the unique nutritional and environmental risk factors that characterise the urban Indian sleep crisis.
References
Abbasi, B., Kimiagar, M., Sadeghniiat, K., Shirazi, M.M., Hedayati, M. and Rashidkhani, B. (2012) ‘The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial’, Journal of Research in Medical Sciences, 17(12), pp. 1161–1169.
Amsterdam, J.D., Li, Y., Soeller, I., Rockwell, K., Mao, J.J. and Shults, J. (2009) ‘A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder’, Journal of Clinical Psychopharmacology, 29(4), pp. 378–382. Available at: https://doi.org/10.1097/jcp.0b013e3181ac935c
Benke, D., Barberis, A., Kopp, S., Macdonald, R.L., Sigel, E. and Möhler, H. (2009) ‘GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts’, Neuropharmacology, 56(1), pp. 174–181. Available at: https://doi.org/10.1016/j.neuropharm.2008.06.013
Bent, S., Padula, A., Moore, D., Patterson, M. and Mehling, W. (2006) ‘Valerian for sleep: a systematic review and meta-analysis’, American Journal of Medicine, 119(12), pp. 1005–1012. Available at: https://doi.org/10.1016/j.amjmed.2006.02.026
Brzezinski, A., Vangel, M.G., Wurtman, R.J., Norrie, G., Zhdanova, I., Ben-Shushan, A. and Ford, I. (2005) ‘Effects of exogenous melatonin on sleep: a meta-analysis’, Sleep Medicine Reviews, 9(1), pp. 41–50. Available at: https://doi.org/10.1016/j.smrv.2004.06.004
Chattu, V.K., Manzar, M.D., Kumary, S., Burman, D., Spence, D.W. and Pandi-Perumal, S.R. (2018) ‘The global problem of insufficient sleep and its serious public health implications’, Healthcare, 7(1), p. 1. Available at: https://doi.org/10.3390/healthcare7010001
Dakshinamurti, K., Sharma, S.K. and Geiger, J.D. (1990) ‘Neuroprotective actions of pyridoxine’, Biochimica et Biophysica Acta – Molecular Cell Research, 1035(1), pp. 227–235.
de Baaij, J.H., Hoenderop, J.G. and Bindels, R.J. (2015) ‘Magnesium in man: implications for health and disease’, Physiological Reviews, 95(1), pp. 1–46. Available at: https://doi.org/10.1152/physrev.00012.2014
Dietz, B.M., Mahady, G.B., Pauli, G.F. and Farnsworth, N.R. (2005) ‘Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro’, Molecular Brain Research, 138(2), pp. 191–197. Available at: https://doi.org/10.1016/j.molbrainres.2005.04.009
Fernández-San-Martín, M.I., Masa-Font, R., Palacios-Soler, L., Sancho-Gómez, P., Calbó-Caldentey, C. and Flores-Mateos, G. (2010) ‘Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials’, Sleep Medicine, 11(6), pp. 505–511. Available at: https://doi.org/10.1016/j.sleep.2009.12.002
Ferracioli-Oda, E., Qawasmi, A. and Bloch, M.H. (2013) ‘Meta-analysis: melatonin for the treatment of primary sleep disorders’, PLOS ONE, 8(5), p. e63773. Available at: https://doi.org/10.1371/journal.pone.0063773
Figueiro, M.G., Wood, B., Plitnick, B. and Rea, M.S. (2011) ‘The impact of light from computer monitors on melatonin levels in college students’, Neuro Endocrinology Letters, 32(2), pp. 158–163.
Grandner, M.A., Jackson, N., Gerstner, J.R. and Knutson, K.L. (2014) ‘Dietary nutrients associated with short and long sleep duration: data from a nationally representative sample’, Appetite, 82, pp. 41–48. Available at: https://doi.org/10.1016/j.appet.2014.06.024
Hartmann, E. and Greenwald, D. (1984) ‘Tryptophan and human sleep: an analysis of 43 studies’, in Schlossberger, H.G., Köhler, W., Linzen, B. and Steinhart, H. (eds.) Progress in Tryptophan and Serotonin Research. Berlin: Walter de Gruyter, pp. 297–304.
Hieu, T.H., Dibas, M., Surber, C., Tran, N.T., Ngo, N.T., Nguyen, C.T., Nguyen, V.K. and Dinh, H.V. (2019) ‘Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: a systematic review and meta-analysis of randomized trials and quasi-randomized trials’, Phytotherapy Research, 33(6), pp. 1604–1615. Available at: https://doi.org/10.1002/ptr.6349
Inagawa, K., Hiraoka, T., Kohda, T., Yamadera, W. and Takahashi, M. (2006) ‘Subjective effects of glycine ingestion before the sleep period on sleep quality’, Sleep and Biological Rhythms, 4(1), pp. 75–77. Available at: https://doi.org/10.1111/j.1479-8425.2006.00193.x
Kimura, K., Ozeki, M., Juneja, L.R. and Ohira, H. (2007) ‘L-Theanine reduces psychological and physiological stress responses’, Biological Psychology, 74(1), pp. 39–45. Available at: https://doi.org/10.1016/j.biopsycho.2006.06.006
Leathwood, P.D., Chauffard, F., Heck, E. and Munoz-Box, R. (1982) ‘Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man’, Pharmacology, Biochemistry and Behavior, 17(1), pp. 65–71. Available at: https://doi.org/10.1016/0091-3057(82)90264-7
Morin, C.M., Bootzin, R.R., Buysse, D.J., Edinger, J.D., Espie, C.A. and Lichstein, K.L. (2006) ‘Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004)’, Sleep, 29(11), pp. 1398–1414. Available at: https://doi.org/10.1093/sleep/29.11.1398
National Nutrition Monitoring Bureau (NNMB) (2012) Diet and Nutritional Status of Rural Population, Prevalence of Hypertension and Diabetes Among Adults and Infant and Young Child Feeding Practices: NNMB Technical Report No. 26. Hyderabad: National Institute of Nutrition.
Nielsen, F.H., Johnson, L.K. and Zeng, H. (2010) ‘Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep’, Magnesium Research, 23(4), pp. 187–193. Available at: https://doi.org/10.1684/mrh.2010.0220
Nobre, A.C., Rao, A. and Owen, G.N. (2008) ‘L-theanine, a natural constituent in tea, and its effect on mental state’, Asia Pacific Journal of Clinical Nutrition, 17(Suppl 1), pp. 167–168.
Panda, S., Taly, A.B., Sinha, S., Gururaj, G., Girish, N. and Bhatt, M. (2012) ‘Sleep-related disorders among a healthy population in South India’, Annals of Indian Academy of Neurology, 15(1), pp. 1–6. Available at: https://doi.org/10.4103/0972-2327.93261
Pandi-Perumal, S.R., Srinivasan, V., Maestroni, G.J., Cardinali, D.P., Poeggeler, B. and Hardeland, R. (2006) ‘Melatonin: nature’s most versatile biological signal?’, FEBS Journal, 273(13), pp. 2813–2838. Available at: https://doi.org/10.1111/j.1742-4658.2006.05322.x
Rao, T.P., Ozeki, M. and Juneja, L.R. (2015) ‘In search of a safe natural sleep aid’, Journal of the American College of Nutrition, 34(5), pp. 436–447. Available at: https://doi.org/10.1080/07315724.2014.926153
Saper, C.B., Scammell, T.E. and Lu, J. (2005) ‘Hypothalamic regulation of sleep and circadian rhythms’, Nature, 437(7063), pp. 1257–1263. Available at: https://doi.org/10.1038/nature04284
Trauner, G., Khom, S., Baburin, I., Ferber, B., Hering, S. and Kopp, B. (2008) ‘Modulation of GABA-A receptors by valerian extracts is related to the content of valerenic acid’, Planta Medica, 74(1), pp. 19–24. Available at: https://doi.org/10.1055/s-2007-993761
Walker, A.F., De Souza, M.C., Vickers, M.F., Abeyasekera, S., Collins, M.L. and Trinca, L.A. (2003) ‘Magnesium supplementation alleviates premenstrual symptoms of fluid retention’, Journal of Women’s Health, 7(9), pp. 1157–1165.
Zanoli, P., Avallone, R. and Baraldi, M. (2000) ‘Behavioral characterisation of the flavonoids apigenin and chrysin’, Fitoterapia, 71(Suppl 1), pp. S117–S123. Available at: https://doi.org/10.1016/s0367-326x(00)00186-3
Zick, S.M., Wright, B.D., Sen, A. and Arnedt, J.T. (2011) ‘Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study’, BMC Complementary and Alternative Medicine, 11, p. 78. Available at: https://doi.org/10.1186/1472-6882-11-78
